Blocknomi
Key Takeaways CMND-100 successfully achieved its primary safety endpoint in a Phase I/IIa trial targeting Alcohol Use Disorder No serious adverse events occurred in the third cohort, demonstrating robust safety…
Related articles
-
Ethereum DeFi Exchange CoW Swap Pauses Protocol Following Website Compromise
Decrypt Published 14.04.2026 21:37
-
Final Days of 95x Potential! BlockDAG’s Final Allocation Nears Limit While Ethena and Polygon Show Diverging Market Strength
BlockchainReporter Published 12.04.2026 16:00
-
Samsung Boosts Tesla (TSLA) DRAM Deliveries by 400% in April 2026
Blocknomi Published 22.04.2026 09:14
-
Infosys (INFY) Stock Teams Up With OpenAI for Enterprise AI Transformation
Blocknomi Published 22.04.2026 15:05
-
Sheri Biggs Reports $250K Bitcoin ETF Purchase in Filing
Blocknomi Published 17.04.2026 17:45
-
Bitcoin 'plebs eat first' mining pool Parasite finds its second BTC block
CoinDesk Published 18.04.2026 13:21
-
Top Crypto to Watch: The SOL ETF Move Every Solana Holder Is Watching as Pepeto Targets 268x
Blocknomi Published 18.04.2026 16:02
-
Bitcoin Shorts Get Rekt as BTC Jumps Above $75K, Hitting 2-Month Price High
Decrypt Published 14.04.2026 14:33